Grow Pharma said it has struck a deal with cannabis and pharma giant Tilray (NASDAQ:TLRY) to import and distribute the latter’s medical cannabis products in the UK.
Patients will have access to the products by obtaining prescriptions privately or via the National Health Service (NHS) and Tilray expects to have them available by March this year.
“We’re proud to join forces with Tilray and provide patients in need with a secure and sustainable supply of the highest-quality medical cannabis products in the UK,” said Pierre van Weperen, the CEO of privately-owned Grow Pharma, in a statement.
Sascha Mielcarek, the managing director of Tilray Europe, added: “As demand continues to ramp up in the UK, Tilray is well-positioned to be a leading supplier of medical cannabis products. Regulations are progressing as more and more countries across Europe are recognizing the benefits of medical cannabis and its potential to improve patients’ quality of life.
“We’re pleased to reaffirm our commitment to delivering medical cannabis to patients in the UK and look forward to offering a variety of GMP-certified, pharmaceutical-grade products in the coming months.”
Grow Pharma is a UK medical cannabis distributor, part of the Grow Group, which runs three business units: Grow Pharma, Grow Trading and Grow Biotech.
Earlier it was reported the group had started trials to extract cannabis-based medical products in the UK, making it only the second company to have done so after GW Pharmaceuticals (NASDAQ:GWPH).
Grow Pharma said it was attempting to replicate and distribute cannabis-based medicinal products (CBMPs) for patients experiencing Brexit disruption to supplies.